Cylembio plus pembrolizumab achieved a clinically relevant 19.4 months median progression free survival (mPFS) compared to 11.0 months mPFS with pembrolizumab alone; study narrowly missed progression ...
Atezolizumab shows no significant benefit over BCG alone in treating high-risk non-muscle invasive bladder cancer, according to the ALBAN trial results.
Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (“Neuphoria” or the “Company”), a clinical-stage biotechnology company developing impactful treatments for neuropsychiatric disorders, today announced that ...
AFFIRM-1 trial did not meet primary endpoint or secondary endpoints Company to conduct strategic review of portfolio and business operations BURLINGTON, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Neupho ...
MSD and Eisai presented the data at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany. The ...
Community-acquired pneumonia is a major global health challenge that disproportionately affects vulnerable populations, ...
Dura-Belt’s Jim Hammond shares his expert insights about designing, manufacturing and maintaining thermoplastic elastic belts ...
Introducing this year's exceptional Black British Business Awards2025 (BBBAwards) winners; representing the very best of entrepreneurs, corporate leaders and innovators from global corporations such ...
Meal prep made easy with AI: Tips from an Extension educator Unsure what to make for dinner, you check your kitchen. A loaf of bread. A bag of baby carrots. A can of pumpkin puree. A package of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback